Safety profile for PEMAZYRE — 1 of 1

The safety profile of PEMAZYRE was investigated in the FIGHT–202 study

In FIGHT-202, the most common AR observed with PEMAZYRE was hyperphosphataemia1

  • The safety of PEMAZYRE was investigated in the FIGHT–202 study in previously treated patients with CCA (N=147)1
 eDetail.safety.modal1.trigger.iconAlt

Serious ARs

 eDetail.safety.modal2.trigger.iconAlt

Specific ARs
and additional information

 eDetail.safety.modal3.trigger.iconAlt

Warnings and precautions



For further safety information, please refer to the PEMAZYRE Swissmedic Professional Information.1


Healthcare professionals are required to report any suspected new or serious side effects. See the “Undesirable effects” section of the Swissmedic Professional Information for the terms and conditions for reporting side effects. Adverse events should also be reported to Incyte immediately by phoning 00800 000 274 23 or via email at eumedinfo@incyte.com.

MOST COMMON ARs OBSERVED WITH
PEMAZYRE (>15%)1

Bar chart showing common ARs observed with PEMAZYRE

Patients (%)

Most common ARs (any grade)